Abiopharma

🔍 MCCORMICK FRANK (Director)

Company: BridgeBio Pharma, Inc. (BBIO)

Report Date: 2026-06-22

Detailed Transactions and Holdings:

• Acquired 3,990 shares of Common Stock (Direct)
  Date: 2026-06-22 | Code: A | equity_swap_involved: 0 | shares_owned_after: 10,579.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-22 | Code: H | nature_of_ownership: By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 | shares_owned_after: 756,665.00 | Footnotes: F3
• Acquired 5,277 shares of Stock Option (Right to Buy) at $68.92 per share (Derivative)
  Date: 2026-06-22 | Code: A | Expires: 2036-06-21 | equity_swap_involved: 0 | shares_owned_after: 5,277.00 | transaction_form_type: 4 | Footnotes: F6

Footnotes:

• F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
• F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• F3: The Reporting Person previously reported a transfer of 352,290 shares on a Form 4 filed June 25, 2024. The reported transfer did not occur, and no change in beneficial ownership took place at that time. The ownership amounts reported herein reflect the Reporting Person's correct holdings and the transfer described in Footnotes 4 and 5.
• F4: Excludes 428,976 shares that were previously held directly by the Reporting Person and were transferred to the Reporting Person's trust account on June 3, 2026.
• F5: Includes 428,976 shares that were previously held directly by the Reporting Person and were transferred to the Reporting Person's trust account on June 3, 2026.
• F6: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.